Date: 2014-06-03
Type of information: Licensing agreement
Compound: immune cell-targeting agents for imaging with Positron Emission Tomography (PET)
Company: ImaginAb (USA - CA) University of California, Los Angeles (UCLA) (USA - CA)
Therapeutic area: Cancer - Oncology - Autoimmune diseases - Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On June 3, 2014, ImaginAb and the Regents of the University of California, Los Angeles (UCLA) have executed a technology licensing agreement relating to novel immune cell-targeting agents for imaging with Positron Emission Tomography (PET). Inflammation and immune response play a fundamental role in a wide variety of diseases including cancer and autoimmune diseases. Under the agreement, ImaginAb gains exclusive access to novel imaging agents that target specific markers of murine T-cells, enabling a new understanding of response to immunotherapeutic drugs in pre-clinical models. These research “ImmunoPET” imaging agents complement ImaginAb’s active clinical development programs, particularly in the cancer immunotherapy space. The imaging of T-cell targets such as CD3 and CD8 has the potential to improve on the limited efficacy of tissue and blood-based biomarker strategies to effectively predict and monitor response to drugs against important targets like PD-1/L1 or CTLA4 checkpoint inhibitors.
Financial terms:
Latest news:
